Taiwanese journal of obstetrics & gynecology · 2026
Thyroid-stimulating hormone-secreting pituitary neuroendocrine tumor (TSH-PitNet) diagnosed during pregnancy and treated with a somatostatin analog.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kawabata Ikuno, Ogawa Jun, Ichikawa Tomoko, Kuwabara Yoshimitsu, Motoda Norio, Tahara Shigeyuki, Suzuki Shunji
Аннотация
OBJECTIVE: Thyroid-stimulating hormone (TSH)-secreting pituitary neuroendocrine tumors (TSH-PitNET) are extremely rare during pregnancy, with limited understanding of their impact.
CASE REPORT: A primiparous woman in her mid-20s was diagnosed with TSH-PitNET during pregnancy following symptoms, including hyperemesis gravidarum and mild palpitation. At 12 weeks of gestation, a blood test revealed that TSH was not suppressed despite elevated thyroid hormone levels, consistent with SITSH (syndrome of inappropriate TSH secretion). No thyroid hormone receptor β (TRβ) mutation was detected. MRI revealed a pituitary macroadenoma, and TSH-PitNET was diagnosed. Monthly lanreotide injections were administered from 18 weeks until term. At 40 weeks, she underwent an emergency cesarean delivery due to severe headache and mild hypertension, delivering a healthy infant. Transsphenoidal macroadenoma resection was performed three months postpartum.
CONCLUSION: This case highlights that a conservative approach with lanreotide and close monitoring can achieve favorable outcomes for both mother and child in TSH-PitNET during pregnancy.
CASE REPORT: A primiparous woman in her mid-20s was diagnosed with TSH-PitNET during pregnancy following symptoms, including hyperemesis gravidarum and mild palpitation. At 12 weeks of gestation, a blood test revealed that TSH was not suppressed despite elevated thyroid hormone levels, consistent with SITSH (syndrome of inappropriate TSH secretion). No thyroid hormone receptor β (TRβ) mutation was detected. MRI revealed a pituitary macroadenoma, and TSH-PitNET was diagnosed. Monthly lanreotide injections were administered from 18 weeks until term. At 40 weeks, she underwent an emergency cesarean delivery due to severe headache and mild hypertension, delivering a healthy infant. Transsphenoidal macroadenoma resection was performed three months postpartum.
CONCLUSION: This case highlights that a conservative approach with lanreotide and close monitoring can achieve favorable outcomes for both mother and child in TSH-PitNET during pregnancy.